DBDinesh S. Bangari

Dinesh S. Bangari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dinesh S. Bangari has a total of 327 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD8 T-cell exhaustion linked with CAR T-cell failure can be mitigated by a non-alpha IL2 receptor agonist

    by Kotaro Arita, Enyu Dai, Xubin Li, Irtiza N. Sheikh, Patrick K Reville, Jared Henderson, Ashley Lauren Wilson, Christan Dillard, Kevin Bowman, Haopeng Yang, et al.

    Chimeric antigen receptor T-cell (CART19) therapy represents a breakthrough for relapsed or refractory large B-cell lymphoma (rrLBCL). However, suboptimal CART19 activity can lead to therapeutic failure and dismal outcomes. Through single cell RNA-sequencing of tumors at the time of progression from CART19, we show that a subset of tumor contain clonally expanded and proliferating populations of CART19 cells that acquire transcriptional features of dysfunction, suggestive of ongoing tumor cell engagement and chronic stimulation. Using an in vitro system to model this process, we show that iterative rechallenge of CART19 cells with target cells drives failure of tumor control associated with acquired transcriptomic features of T-cell dysfunction and reduced IL2 signaling. Pegenzileukin, a non-alpha IL2-receptor agonist, prevented CART19 dysfunction, improving T-cell expansion and tumor control in vitro. To test this concept in vivo, we developed a cell line model from a post-CART19 progression tumor that reproduces the response and failure kinetics observed in the originating patient. In vivo CART19 alone led to transient response followed by progression and secondary central nervous system relapse in this model, while the addition of pegenzileukin to CART19 led to the complete eradication of tumors. This provides mechanism-informed pre-clinical rationale for the use of non-alpha IL2 receptor agonists in combating T-cell exhaustion, a critical mechanism of CART19 failure.


  • Comparative evaluation of artificial intelligence-based and pathologist scoring of murine bile duct hyperplasia

    by Ingeborg M. Langohr, Dev Kumar Das, Dayananda Siddappa, Nathan Pate, Kuldeep Gautam, Sanjit Jha, Rajesh Ugalmugle, Tijo Thomas, Uttara Joshi, Srinivas Rao, et al.

    Bile duct hyperplasia in rodents, caused by chemical cytotoxicity, bile flow interference, or aging, is traditionally assessed through time-consuming microscopic examination by pathologists. We developed a deep learning-based, artificial intelligence (AI) model for quick and accurate assessment of bile duct hyperplasia in mice. The study utilized 127 hematoxylin and eosin-stained, mouse liver whole-slide images (WSIs) digitized using Aperio scanners. A segmentation algorithm with a U-Net architecture and an EfficientNet backbone was trained on 1165 areas from 35 WSIs to identify and quantify bile ducts, measure their area percentage using a supervised method, and categorize them into grades 0 to 4 using an unsupervised method. The model was validated on 24 WSIs and tested on 68 WSIs, all independently scored by 3 veterinary pathologists using consensus criteria. The segmentation model achieved Dice scores of 91.75% in training and 85.88% in validation. Testing revealed high sensitivity (95%), specificity (97%), and Dice score (95.45%), indicating robust model accuracy. Model-predicted grades showed strong correlation ( r 2 s = 0.86) with pathologists’ consensus scores. This AI-driven approach has the potential to enhance the accuracy and efficiency of bile duct hyperplasia assessments in rodent studies, paving the way for more standardized, objective, and high-throughput histological evaluations in preclinical research.

  • Open Access

    Targeting MAPK-dependent pathways to modulate reactive astrocyte pathology in neurodegeneration

    by Iqra Pervaiz, Anna S. Blazier, Ivan Nyarko-Danquah, Hendrik Wesseling, Adriana Ramos, Lisa Woodworth, Tatyana V. Taksir, Sean K. Ryan, Gregory Wirak, Zhonglin Zhao, et al.

    Reactive astrocytes play a crucial role in the pathogenesis of neurodegenerative diseases; however, the mechanisms underlying glial cell interactions remain poorly understood. Here, we show that human primary astrocytes and iPSC-derived astrocytes in a tri-culture system adopt a reactive state with a distinct molecular phenotype overlapping with transcriptomic signatures observed in ALS astrocytes. Integrated proteomic and phosphoproteomic analyses revealed dysregulated cytoskeletal remodeling and kinase signaling in reactive astrocytes. Surface marker screening identified ICAM-1 as a novel in-vitro marker, validated in ALS spinal cord. Functionally, reactive astrocytes induced neurotoxicity and altered neuronal activity. To elucidate mechanisms regulating neurotoxicity, a phenotypic small molecule screen identified MAP kinase as a functional regulator, with subsequent single-nucleus RNA sequencing uncovering dysregulated signaling pathways modulated by MAPK inhibition in the tri-culture system. Together, these complementary approaches define the molecular landscape of reactive astrocytes, providing a systems-level framework for exploring disease mechanisms and therapeutic strategies in neurodegeneration.

  • Open Access

    PD-1–targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer

    by Isaraphorn Pratumchai, Marie Bernardo, Julien Tessier, Jaroslav Zak, Kristi L. Marquardt, Joon Sang Lee, Maheeka Bimal, Ahyun Choi, Anthony M. Byers, Mikielia G. Devonish, et al.

    Immune checkpoint inhibitors have transformed cancer therapy, yet many patients fail to achieve durable responses due to insufficient T cell reinvigoration. Cytokines offer promise for enhancing immunotherapy, but their clinical use is limited by toxicity and a narrow therapeutic index. Immunocytokines, engineered fusion proteins combining antibody specificity with cytokine activity, aim to overcome these challenges by targeting cytokine delivery to immune cells or the tumor microenvironment. We describe SAR445877 (SAR’877), a potentially novel PD-1–targeted immunocytokine that fuses a high-affinity anti–PD-1 antibody with a detuned IL-15/IL-15Rα sushi domain complex. SAR’877 blocks PD-1/PD-L1 and PD-1/PD-L2 interactions while selectively delivering IL-15 signals to PD-1 + T cells, enhancing proliferation and activation of antigen-experienced CD8 + and CD4 + T cells and NK cells, while minimizing systemic inflammation. Mechanistically, SAR’877 activates STAT5 signaling in PD-1 + lymphocytes and restores effector function in exhausted T cells. In preclinical models, a murine surrogate of SAR’877 accelerated viral clearance and induced robust antitumor immunity by expanding cytotoxic CD8 + T cells and promoting Th1 polarization. Notably, SAR’877 outperformed anti–PD-1 plus untargeted IL-15, highlighting the therapeutic potential of targeted IL-15 delivery. These findings position SAR’877 as a promising next-generation immunotherapy with enhanced efficacy and reduced cytokine-associated toxicities.


  • Neuro Omics: Translational Neuropathology Applications of Spatial Technologies From Nonclinical Models to Human Disease

    by Dinesh S. Bangari, Saravanan Kaliyaperumal, Nathaniel Roscoe, Oded Foreman, Kerstin Hahn, LaTasha K. Crawford, Elizabeth Buza, Alok K. Sharma

    The basis for current and future neurologic disease research and therapeutic discovery and development is rooted in the understanding of genetic, transcriptional, and molecular expression profiles of cells and their spatial interplays in anatomical context. Neuro omics aim to analyze all possible molecular and morphological types within the nervous system using specific methods such as genomics, transcriptomics, proteomics, metabolomics, and pathomics (ie, radiology and histology). In this scientific session of the Society of Toxicologic Pathology’s 44th Annual Symposium, speakers with diverse experience in drug discovery and nonclinical development presented scientific principles and practical applications of some of the emerging omics technologies as applied to the pursuit of target discovery, preclinical safety, and mechanistic investigations of novel human therapeutics. Spanning both human biology, such as Alzheimer disease, and nonclinical models, session speakers also shared their insights on the promise as well as pitfalls of the omics workflow in nonclinical drug development laboratories.

  • Neurodegenerative Diseases: Pathogenesis and Preclinical Models for Translational Drug Discovery

    by Laura Fusaro, Dinesh S. Bangari, R. Jeroen Pasterkamp, Javier Fernández-Ruiz, Sameh A. Youssef, Alok K. Sharma

    The fourth session of the 2024 European Society of Toxicologic Pathology (ESTP) Congress brought together lectures focused on the use of in vitro and in vivo models to investigate neurodegenerative diseases. Four presentations highlighted various aspects of neurodegenerative diseases including dementia, immune-mediated conditions, and neuromuscular disorders. The session began with an overview of animal models of dementia underscoring their critical role in understanding disease pathogenesis and supporting the development of effective therapeutic drugs. Subsequent presentations investigated immunological self-tolerance in autoimmune neurodegenerative diseases, such as multiple sclerosis and Guillain-Barré syndrome, and the application of in vitro models to study neuromuscular diseases such as amyotrophic lateral sclerosis. The final presentation examined cannabinoid-based therapeutic options for treating neurodegenerative diseases, highlighting their potential in neuroprotection and neurorepair. This session provided valuable insights into the latest research and advancements in neurodegenerative disease modeling and therapy, offering promising directions for improved modeling and therapeutic strategies.


  • Applications of Molecular Pathology: An Evolving Approach to Toxicologic Pathology

    by Ingrid Cornax, Dinesh S. Bangari, Vinicius Carreira, Kyathanahalli S. Janardhan

  • Points to Consider From the ESTP Pathology 2.0 Working Group: Overview on Spatial Omics Technologies Supporting Drug Discovery and Development

    by Kerstin Hahn, Bettina Amberg, Josep M. Monné Rodriguez, Mieke Verslegers, Byunghak Kang, Hans Wils, Chandra Saravanan, Dinesh S. Bangari, Simon Y. Long, Sameh A Youssef, et al.

    Recent advances in bioanalytical and imaging technologies have revolutionized our ability to assess complex biological and pathological changes within tissue samples. Spatial omics, a rapidly evolving technology, enables the simultaneous detection of multiple biomolecules in tissue sections, allowing for high-dimensional molecular profiling within tissue microanatomical contexts. This offers a powerful opportunity for precise, multidimensional exploration of complex disease pathophysiology. The Pathology 2.0 working group within the European Society of Toxicologic Pathology (ESTP) includes a subgroup dedicated to spatial omics technologies. Their primary goal is to raise awareness about these emerging technologies and their potential applications in discovery and toxicologic pathology. This review provides an overview of commonly used, commercially available platforms for transcriptomic, proteomic, and multiomic analysis, discussing technical aspects and illustrative examples of their applications. To harness the power of spatial omics for translational drug discovery and human safety risk assessment, we emphasize the important role of pathologists at every stage of the workflow—from hypothesis generation to sample preparation, data analysis, and interpretation. Spatial omics technologies offer novel opportunities in target discovery, lead selection, preclinical assessment, and clinical development in compound development.


  • European Society of Toxicologic Pathology—Pathology 2.0 Mass Spectrometry Imaging Special Interest Group: Mass Spectrometry Imaging in Diagnostic and Toxicologic Pathology for Label-Free Detection of Molecules—From Basics to Practical Applications

    by Enrico Vezzali, Michael Becker, Fernando Romero-Palomo, Marjolein van Heerden, Caroline Chipeaux, Gregory Hamm, Dinesh S. Bangari, Thomas Lemarchand, Barbara Lenz, Bogdan Munteanu, et al.

    Mass Spectrometry Imaging (MSI) is a powerful tool to understand molecular pathophysiology and therapeutic and toxicity mechanisms, as well as for patient stratification and precision medicine. MSI, a label-free technique offering detailed spatial information on a large number of molecules in different tissues, encompasses various techniques including Matrix-Assisted Laser Desorption Ionization (MALDI), Desorption Electrospray Ionization (DESI), and Secondary Ion Mass Spectrometry (SIMS) that can be applied in diagnostic and toxicologic pathology. Given the utmost importance of high-quality samples, pathologists play a pivotal role in providing comprehensive pathobiology and histopathology knowledge, as well as information on tissue sampling, orientation, morphology, endogenous biomarkers, and pathogenesis, which are crucial for the correct interpretation of targeted experiments. This article introduces MSI and its fundamentals, and reports on case examples, determining the best suited technology to address research questions. High-level principles and characteristics of the most used modalities for spatial metabolomics, lipidomics and proteomics, sensitivity and specific requirements for sample procurement and preparation are discussed. MSI applications for projects focused on drug metabolism, nonclinical safety assessment, and pharmacokinetics/pharmacodynamics and various diagnostic pathology cases from nonclinical and clinical settings are showcased.